Cannabinol β-O-Glucoside Inhibitors of the Keap1-Nrf2 Interaction: A Novel Therapeutic Strategy for Parkinson’s Disease
- DOI
- 10.1021/acsmedchemlett.6c00156
- Published
- 2026-09-01
- Container
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1021/acsmedchemlett.6c00156,
title = {Cannabinol
β-O-Glucoside Inhibitors of
the Keap1-Nrf2 Interaction: A Novel Therapeutic Strategy for Parkinson’s
Disease},
author = {Prashant Deshmukh and Snehal Aouti and Ashok Sridhar and Padmini Kommu and Amrutha K and Sarika Singh and Yedukondalu Nalli and Aneeza Noor and Bharath M. M. Srinivas and Asif Ali and Balasundaram Padmanabhan},
year = {2026},
journal = {ACS Medicinal Chemistry
Letters},
doi = {10.1021/acsmedchemlett.6c00156},
url = {https://doi.org/10.1021/acsmedchemlett.6c00156}
}RIS
TY - JOUR TI - Cannabinol β-O-Glucoside Inhibitors of the Keap1-Nrf2 Interaction: A Novel Therapeutic Strategy for Parkinson’s Disease AU - Prashant Deshmukh AU - Snehal Aouti AU - Ashok Sridhar AU - Padmini Kommu AU - Amrutha K AU - Sarika Singh AU - Yedukondalu Nalli AU - Aneeza Noor AU - Bharath M. M. Srinivas AU - Asif Ali AU - Balasundaram Padmanabhan PY - 2026 JO - ACS Medicinal Chemistry Letters DO - 10.1021/acsmedchemlett.6c00156 UR - https://doi.org/10.1021/acsmedchemlett.6c00156 ER -
APA
Deshmukh, P., Aouti, S., Sridhar, A., Kommu, P., K, A., Singh, S., Nalli, Y., Noor, A., Srinivas, B. M. M., Ali, A., & Padmanabhan, B. (2026). Cannabinol β-O-Glucoside Inhibitors of the Keap1-Nrf2 Interaction: A Novel Therapeutic Strategy for Parkinson’s Disease. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/acsmedchemlett.6c00156
Source records
- crossref · retrieved 2026-11-10T20:09:13.903Z